Payment overview · 2025
General Payments
$2,465.40
108 reported records · 24 companies
Healthcare provider profile · identity verified
Arman Hekmati, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · LOS ANGELES, CA · NPI 1326080128
Verified facts
What the public records show
CMS Open Payments records show Arman Hekmati, M.D. received $2,465.40 in general payments during 2025 across 108 reported records.
Amgen Inc. accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Gemtesa, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Tezspire, Trelegy Ellipta, Trintellix.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Prolia by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 22824 records involving 7320 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Tezspire by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Tezspire by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 310 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 290 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $330.35 | 13.4% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $293.64 | 11.9% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $213.51 | 8.7% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $164.90 | 6.7% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $155.63 | 6.3% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $148.93 | 6.0% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $133.22 | 5.4% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $123.25 | 5.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $105.28 | 4.3% | 4 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $102.23 | 4.2% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $87.80 | 3.6% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $87.14 | 3.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $83.11 | 3.4% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $77.99 | 3.2% | 3 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $68.23 | 2.8% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $60.84 | 2.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.74 | 2.4% | 3 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $43.80 | 1.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.59 | 1.1% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $23.51 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.94 | 0.9% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $18.67 | 0.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.15 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.95 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,465.40 | 108 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $213.51 | 9 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $164.90 | 7 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $148.93 | 7 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $123.25 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $122.61 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $113.14 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.28 | 4 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $102.23 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $99.22 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $87.14 | 4 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $86.71 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $83.11 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $80.85 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $77.99 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $68.34 | 3 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $68.23 | 3 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $66.02 | 3 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $64.54 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $60.84 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $60.81 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $59.74 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.37 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.37 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.93 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $43.80 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $43.80 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $43.80 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $42.49 | 2 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.42 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| Linzess Normalized: linzess |
Drug | IRONWOOD PHARMACEUTICALS, INC | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 45 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 93 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Linzess linzess |
2025 | Linzess | 2024 | 152 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 310 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 212 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
50 | 34 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 22824 supporting records · 7320 recipient NPIs · example record 1226871881 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 15 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
152 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
310 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
212 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
290 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
80 | 77 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
93 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
109 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 553 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 550 | 136 |
| Atorvastatin Calcium | Atorvastatin Calcium | 507 | 135 |
| Metformin Hcl | Metformin Hcl | 408 | 103 |
| Escitalopram Oxalate | Escitalopram Oxalate | 405 | 92 |
| Losartan Potassium | Losartan Potassium | 391 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 386 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 358 | 91 |
| Gabapentin | Gabapentin | 337 | 91 |
| Mounjaro | Tirzepatide | 310 | 51 |
| Famotidine | Famotidine | 305 | 74 |
| Donepezil Hcl | Donepezil Hcl | 300 | 65 |
| Eliquis | Apixaban | 290 | 60 |
| Potassium Chloride | Potassium Chloride | 255 | 66 |
| Diclofenac Sodium | Diclofenac Sodium | 252 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 67 |
| Mirtazapine | Mirtazapine | 249 | 57 |
| Dexlansoprazole Dr | Dexlansoprazole | 229 | 39 |
| Meloxicam | Meloxicam | 226 | 71 |
| Montelukast Sodium | Montelukast Sodium | 220 | 49 |
| Simvastatin | Simvastatin | 215 | 42 |
| Ozempic | Semaglutide | 212 | 41 |
| Lorazepam | Lorazepam | 195 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 193 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 187 | 45 |
| Memantine Hcl | Memantine Hcl | 184 | 42 |
| Omeprazole | Omeprazole | 183 | 45 |
| Cefdinir | Cefdinir | 182 | 154 |
| Trazodone Hcl | Trazodone Hcl | 181 | 34 |
| Furosemide | Furosemide | 179 | 56 |
| Levofloxacin | Levofloxacin | 178 | 136 |
| Vascepa | Icosapent Ethyl | 178 | 28 |
| Allopurinol | Allopurinol | 176 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 26 |
| Januvia | Sitagliptin Phosphate | 157 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 38 |
| Linzess | Linaclotide | 152 | 26 |
| Lisinopril | Lisinopril | 135 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 36 |
| Tramadol Hcl | Tramadol Hcl | 118 | 39 |
| Jardiance | Empagliflozin | 117 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 31 |
| Ketoconazole | Ketoconazole | 110 | 56 |
| Trintellix | Vortioxetine Hydrobromide | 109 | 19 |
| Divalproex Sodium | Divalproex Sodium | 108 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 107 | 89 |
| Alprazolam | Alprazolam | 106 | 25 |
| Azithromycin | Azithromycin | 102 | 84 |
| Xarelto | Rivaroxaban | 102 | 18 |
| Synthroid | Levothyroxine Sodium | 101 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 24 |
| Ezetimibe | Ezetimibe | 98 | 26 |
| Gemtesa | Vibegron | 93 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 19 |
| Carvedilol | Carvedilol | 92 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 41 |
| Sertraline Hcl | Sertraline Hcl | 89 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 88 | 19 |
| Hydrocortisone | Hydrocortisone | 82 | 23 |
| Metformin Hcl Er | Metformin Hcl | 82 | 23 |
| Finasteride | Finasteride | 81 | 23 |
| Paxlovid | Nirmatrelvir/Ritonavir | 80 | 77 |
| Celecoxib | Celecoxib | 76 | 22 |
| Atenolol | Atenolol | 68 | 17 |
| Clonazepam | Clonazepam | 68 | 15 |
| Myrbetriq | Mirabegron | 68 | 12 |
| Nateglinide | Nateglinide | 68 | 11 |
| Mupirocin | Mupirocin | 64 | 48 |
| Icosapent Ethyl | Icosapent Ethyl | 62 | 18 |
| Memantine Hcl Er | Memantine Hcl | 62 | 13 |
| Lidocaine | Lidocaine | 60 | 16 |
| Repatha Sureclick | Evolocumab | 59 | 12 |
| Trulicity | Dulaglutide | 58 | suppressed |
| Bumetanide | Bumetanide | 55 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 15 |
| Olanzapine | Olanzapine | 54 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | suppressed |
| Torsemide | Torsemide | 53 | 13 |
| Alendronate Sodium | Alendronate Sodium | 51 | 11 |
| Prolia | Denosumab | 50 | 34 |
| Creon | Lipase/Protease/Amylase | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | 11 |
| Digoxin | Digoxin | 48 | 11 |
| Dutasteride | Dutasteride | 48 | 11 |
| Clonidine Hcl | Clonidine Hcl | 47 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 15 |
| Glipizide | Glipizide | 47 | suppressed |
| Pregabalin | Pregabalin | 47 | 13 |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 45 | 12 |
| Entresto | Sacubitril/Valsartan | 45 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 41 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 14 |
| Diazepam | Diazepam | 40 | suppressed |
| Ertapenem | Ertapenem Sodium | 40 | suppressed |
| Telmisartan | Telmisartan | 40 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 36 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 19 |
| Prednisone | Prednisone | 35 | 23 |
| Repatha Syringe | Evolocumab | 35 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 18 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | 12 |
| Primidone | Primidone | 32 | suppressed |
| Repaglinide | Repaglinide | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | 13 |
| Clotrimazole | Clotrimazole | 30 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Colchicine | Colchicine | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Dulera | Mometasone/Formoterol | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 26 | 25 |
| Latanoprost | Latanoprost | 25 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 18 |
| Dexilant | Dexlansoprazole | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Tezspire | Tezepelumab-Ekko | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Motegrity | Prucalopride Succinate | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Klor-Con 10 | Potassium Chloride | 22 | suppressed |
| Kombiglyze Xr | Saxagliptin Hcl/Metformin Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | 15 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Lumigan | Bimatoprost | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 12 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Edarbi | Azilsartan Medoxomil | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Silodosin | Silodosin | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Cialis | Tadalafil | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 18 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | 11 |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 11 |
| Irbesartan | Irbesartan | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Xofluza | Baloxavir Marboxil | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,465.40 · 108 records | Amgen Inc. | AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, DUPIXENT, ENTRESTO, EVENITY, FARXIGA, Flector, GEMTESA, KISUNLA, KRYSTEXXA, Kerendia, LEQVIO, Leqembi, Licart, Linzess, MOUNJARO, NUCALA, OTEZLA, Ozempic, PEMGARDA, RELISTOR, REPATHA, REXULTI, Rybelsus, SMARTVEST, TEPEZZA, TEZSPIRE, TRELEGY ELLIPTA, TRINTELLIX, TRULANCE, Tirosint, VOQUEZNA, VYNDAQEL, WELLBUTRIN, ZENPEP, ZEPBOUND | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error